Ozempic and other GLP-1 RAs could slow progression of some cancers (medicalxpress.com)

• GLP-1 RAs show potential to slow cancer growth
• Study based on preclinical and early clinical data
• Implications for Irish oncology and public health

"A new study suggests that GLP-1 receptor agonists, such as Ozempic, may slow the progression of certain cancers. This has potentially significant implications for oncology practice and public health, particularly in Ireland where these drugs are widely used."